When cells become a drug. Endothelial progenitor cells for cardiovascular therapy: Aims and reality

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 1, 2010, Pages 1-10

  Burba, Ilaria ^a   Devanna, Paolo ^a   Pesce, Maurizio ^a  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

Angiogenesis; Endothelial progenitor cell; Enhancement strategy; GMP; Ischemia

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1; TISSUE SCAFFOLD;

BIOLOGICAL PEST CONTROL; CARDIOVASCULAR DISEASE; CELL CULTURE; CELL ISOLATION; DRUG MANUFACTURE; ENDOTHELIUM CELL; EUROPEAN UNION; GENETIC ENGINEERING; HUMAN; IN VITRO STUDY; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PATENT; PRIORITY JOURNAL; QUALITY CONTROL; REGENERATIVE MEDICINE; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE REPAIR;

ADULT; ADULT STEM CELLS; ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HUMANS; LIFE STYLE; MYOCARDIAL ISCHEMIA; REGENERATIVE MEDICINE; RISK FACTORS; STEM CELL TRANSPLANTATION;

EID: 77951121418     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010790192610     Document Type: Review

References (90)

1. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257(11): 491-496.
2. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385(6619): 810-813.
3. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-872.
4. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-676.
5. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature 2008; 453(7193): 322-329.
6. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008; 451(7181): 937-942.
7. Young PP, Vaughan DE, Hatzopoulos AK. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog Cardiovasc Dis 2007; 49(6): 421-429.
8. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275(5302): 964-967.
9. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5(4): 434-438.
10. Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106(24): 3009-3017.
11. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106(15): 1913-1918.
12. Kang S, Yang YJ, Li CJ, Gao RL. Effects of intracoronary autologous bone marrow cells on left ventricular function in acute myocardial infarction: A systematic review and meta-analysis for randomized controlled trials. Coron Artery Dis 2008; 19(5): 327-335.
13. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Arch Intern Med 2007; 167(10): 989-997.
14. Lipinski MJ, Biondi-Zoccai GG, Abbate A, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007; 50(18): 1761-1767.
15. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: A systematic review. Eur Heart J 2008; 29(15): 1807-1818.
16. Martin-Rendon E, Brunskill S, Doree C, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2008; 4: CD006536.
17. Finney MR, Greco NJ, Haynesworth SE, et al. Direct comparison of umbilical cord blood versus bone marrow-derived endothelial precursor cells in mediating neovascularization in response to vascular ischemia. Biol Blood Marrow Transplant 2006; 12(5): 585-593.
18. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24(2): 288-293.
19. Yoon CH, Hur J, Park KW, et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005; 112(11): 1618-1627.
20. Timmermans F, Plum J, Yoder MC, Ingram DA, Vandekerckhove B, Case J. Endothelial progenitor cells: Identity defined? J Cell Mol Med 2009; 13(1): 87-102.
21. Timmermans F, van Hauwermeiren F, de Smedt M, et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007; 27(7): 1572-1579.
22. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 2005; 106(5): 1525-1531.
23. Prater DN, Case J, Ingram DA, Yoder MC. Working hypothesis to redefine endothelial progenitor cells. Leukemia. 2007; 21(6): 1141-1149.
24. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104(9): 2752-2760.
25. Rohde E, Bartmann C, Schallmoser K, et al. Immune cells mimic the morphology of endothelial progenitor colonies in vitro. Stem Cells 2007; 25(7): 1746-1752.
26. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003; 108(20): 2511-2516.
27. Rohde E, Malischnik C, Thaler D, et al. Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006; 24(2): 357-367.
28. Hur J, Yang HM, Yoon CH, et al. Identification of a novel role of T cells in postnatal vasculogenesis: Characterization of endothelial progenitor cell colonies. Circulation 2007; 116(15): 1671-1682.
29. Sieveking DP, Ng MK. Cell therapies for therapeutic angiogenesis: Back to the bench. Vasc Med 2009; 14(2): 153-166.
30. Timmermans F, Plum J, Yoder MC, Ingram DA, Vandekerckhove B, Case J. Endothelial progenitor cells: Identity defined? J Cell Mol Med 2009; 13(1): 87-102.
31. Pelosi E, Valtieri M, Coppola S, et al. Identification of the hemangioblast in postnatal life. Blood 2002; 100(9): 3203-3208.
32. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109(5): 1801-1809.
33. Piaggio G, Rosti V, Corselli M, et al. Endothelial colony forming cells (ECFCs) from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. Blood 2009; 114(14): 3127-3130.
34. Wang L, Li L, Shojaei F, et al. Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity 2004; 21(1): 31-41.
35. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: Insights from a novel human angiogenesis assay. J Am Coll Cardiol 2008; 51(6): 660-668.
36. Gaipa G, Tilenni M, Straino S, et al. GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy. J Cell Mol Med 2009 [Epub ahead of print].
37. Popa, E.R., Harmsen, M.C., Van der Strate, B.W.A., van Luyn, M.J.A., Hendricks, M.: US2005028923 (2009).
38. Wary, K.K., Zhao, Y., Malik, A.B., Zhao, Y.: US20080206200 (2008).
39. Yoder M.C., Ingram D.A.: US20050266556 (2005).
40. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89(1): E1-7.
41. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348(7): 593-600.
42. Marchetti V, Menghini R, Rizza S, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006; 55(8): 2231-2237.
43. de Falco E, Avitabile D, Totta P, et al. Altered Sdf-1-mediated diffferentiation of bone marrow-derived endothelial progenitor cells in diabetes mellitus. J Cell Mol Med 2009 [Epub ahead of print].
44. Seeger FH, Haendeler J, Walter DH, et al. P38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 2005; 111(9): 1184-1191.
45. Brunner S, Engelmann MG, Franz WM. Stem cell mobilisation for myocardial repair. Expert Opin Biol Ther 2008; 8(11): 1675-1690.
46. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: A comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007; 28(6): 766-772.
47. Seeger FH, Zeiher AM, Dimmeler S. Cell-enhancement strategies for the treatment of ischemic heart disease. Nat Clin Pract Cardiovasc Med 2007; 4 Suppl 1: S110-113.
48. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154(2): 355-363.
49. Rivard A, Fabre JE, Silver M, et al. Age-dependent impairment of angiogenesis. Circulation 1999; 99(1): 111-120.
50. Iwaguro H, Asahara T. Endothelial progenitor cell culture and gene transfer. Methods Mol Med 2005; 112: 239-247.
51. Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002; 105(6): 732-738.
52. Nabel EG. Stem cells combined with gene transfer for therapeutic vasculogenesis: Magic bullets? Circulation 2002; 105(6): 672-674.
53. Harats, D., Greenberger, S.: US20070286845 (2007).
54. Sugyama, H., Hosen, N., Hastie, N.D.: US20080003637 (2008).
55. Peled, T.: US20090004191 (2009).
56. De Falco E, Porcelli D, Torella AR, et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004; 104(12): 3472-3482.
57. Zemani F, Silvestre JS, Fauvel-Lafeve F, et al. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 2008; 28(4): 644-650.
58. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003; 107(9): 1322-1328.
59. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004; 110(21): 3300-3305.
60. Hiasa K, Ishibashi M, Ohtani K, et al. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004; 109(20): 2454-2461.
61. Zheng H, Dai T, Zhou B, et al. SDF-1alpha/CXCR4 decreases endothelial progenitor cells apoptosis under serum deprivation by PI3K/Akt/eNOS pathway. Atherosclerosis 2008 [Epub ahead of print].
62. Alitalo K., Eriksson U., Carmeliet P., Li X., Collen D., Yla- Herttuala S., Salven P., Rajantie I.: US20040248796 (2004).
63. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98(18): 10344-10349.
64. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102(4): 1340-1346.
65. Walsh, K.: US20046689807 (2004).
66. Honold J, Lehmann R, Heeschen C, et al. Effects of granulocyte colony simulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arterioscler Thromb Vasc Biol 2006; 26(10): 2238-2243.
67. Ripa RS, Kastrup J. G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction-a relevant treatment? Exp Hematol 2008; 36(6): 681-686.
68. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3- kinase/Akt pathway. J Clin Invest 2001; 108(3): 391-397.
69. Zeiher, A., Dimmeler, S., Heeschen, C., Ruetten, H.: US20050101599 (2005).
70. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103(24): 2885-2890.
71. Griese DP, Ehsan A, Melo LG, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: Implications for cell-based vascular therapy. Circulation 2003; 108(21): 2710-2715.
72. Kong D, Melo LG, Mangi AA, et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004; 109(14): 1769-1775.
73. Currie, M.G., Talley, J.J., Cali, B.: US20090054450 (2009).
74. Bemis, G.W.: US20006147080 (2000).
75. Flameng, W., De Visscher, G.: US20070264306 (2007).
76. Christman KL, Lee RJ. Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol 2006; 48(5): 907-913.
77. Kofidis T, Lebl DR, Martinez EC, Hoyt G, Tanaka M, Robbins RC. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation 2005; 112(9 Suppl): I173-177.
78. Callegari A, Bollini S, Iop L, et al. Neovascularization induced by porous collagen scaffold implanted on intact and cryoinjured rat hearts. Biomaterials 2007; 28(36): 5449-5461.
79. Davis ME, Motion JP, Narmoneva DA, et al. Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 2005; 111(4): 442-450.
80. Goren A, Dahan N, Goren E, Baruch L, Machluf M. Encapsulated human mesenchymal stem cells: A unique hypoimmunogenic platform for long-term cellular therapy. FASEB J 2009; published online before print September 2, 2009 as doi: 10.1096/fj.09-131888.
81. Orive G, Hernandez RM, Gascon AR, et al. Cell encapsulation: Promise and progress. Nat Med 2003; 9(1): 104-107.
82. Wendel HP, Avci-Adali M, Ziemer G. Endothelial progenitor cell capture stents - hype or hope? Int J Cardiol 2009 [Epub ahead of print].
83. Schussler, O., Michelot, R.: WO2009007531 (2009).
84. Gong, J.P., Osada, Y., Chen, Y.: US7435594 (2008).
85. Isner, J., Asahara, T.: US20040228835 (2004).
86. Sefton, M.V.: US4353888 (1982).
87. Dionne, K.E., Hegre, O.D., Flanagan, T.R., Hazlett, T.F., Doherty, E.J.: US5773286 (1998).
88. Kutrik, M.J.B., Cottone, R.J. Jr., Rowland, S.M.: US7037332 (2006).
89. Cottone, R.J. Jr., Rowland, S.M., Parker, S.: US20070129789 (2007).
90. Hamilton, P.T., Kenan, D.J., Solan, A.K.: US7531505 (2009).